Paclical (Ovarian Cancer) Analysis and Forecasts to 2020


#28300

33pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, "Paclical (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Paclical sales estimates for the US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US and EU5
  • Analysis and review of Paclical including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Paclical including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2012-2020 for Paclical in the US and EU5

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 7


3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11


4 TumorNodeMetastases (TNM) Classification of Ovarian Cancer 12


5 Paclical 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.3.1 Phase I/II trial 15
5.3.2 Phase III trial 15
5.3.3 Results 16
5.4 Trial History of Paclical 16
5.5 Factors affecting sales of Paclical 16
5.5.1 Advantage over Taxol 16
5.5.2 Reduced Side Effects 16
5.5.3 New Generation Drug 16
5.5.4 Niche Market 17
5.5.5 Orphan Drug Designation in US and in Europe 17
5.5.6 Blockbuster potential with additional indications 17
5.6 Drug Evaluation 17
5.6.1 Drug Risk Benefit Score 17
5.6.2 Intensity of competition 18
5.7 Sales Forecasts 18
5.7.1 Target patient pool of Paclical 19
5.7.2 Dosing 19
5.7.3 Market Penetration 19
5.7.4 Annual cost of Therapy 20
5.7.5 Sales Projections of Paclical 21


6 Ovarian Cancer Market: Appendix 29
6.1 Market Definitions 29
6.2 List of Abberiviations 29
6.3 Research Methodology 29
6.3.1 Coverage 29
6.3.2 Secondary Research 29
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 30
6.3.6 Net Annual Dosing 31
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 32
6.5 Disclaimer 33
6.6 Sources 33


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Table 3: Detailed TNM Classification 13
Table 4: Trial History of Paclical 16
Table 5: Drug Risk Benefit Score of Paclical 17
Table 6: Estimated Annual Cost of Therapy of Paclical, 2012 20
Table 7: Paclical, Ovarian Cancer, Global, Sales Forecasts ($m), 20122020 21
Table 8: Paclical, Ovarian Cancer, The US, Sales Forecasts ($m), 20122020 22
Table 9: Paclical, Ovarian Cancer, The UK, Sales Forecasts ($m), 20122020 23
Table 10: Paclical, Ovarian Cancer, France, Sales Forecasts ($m), 20122020 24
Table 11: Paclical, Ovarian Cancer, Germany, Sales Forecasts ($m), 20122020 25
Table 12: Paclical, Ovarian Cancer, Italy, Sales Forecasts ($m), 20122020 26
Table 13: Paclical, Ovarian Cancer, Spain, Sales Forecasts ($m), 20122020 27


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 20082030 9
Figure 4: Oncology, Worldwide, Incidence (in million), 20082030 10
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 20082030 10
Figure 6: Broad Classification of Ovarian Cancer 12
Figure 7: Classification of Ovarian Cancer 14
Figure 8: Drug Model Diagram of Paclical 19
Figure 9: Paclical, Ovarian Cancer, Global, Sales Forecasts ($m), 20122020 21
Figure 10: Paclical, Ovarian Cancer, The US, Sales Forecasts ($m), 20122020 22
Figure 11: Paclical, Ovarian Cancer, The UK, Sales Forecasts ($m), 20122020 23
Figure 12: Paclical, Ovarian Cancer, France, Sales Forecasts ($m), 20122020 24
Figure 13: Paclical, Ovarian Cancer, Germany, Sales Forecasts ($m), 20122020 25
Figure 14: Paclical, Ovarian Cancer, Italy, Sales Forecasts ($m), 20122020 26
Figure 15: Paclical, Ovarian Cancer, Spain, Sales Forecasts ($m), 20122020 27
Figure 16: Paclical, Ovarian Cancer, The US and EU5, Sales Distribution (%), 2019 28
Figure 17: Drug Model Diagram 31
Figure 18: Patients Approved for the Drug 31